FMO5 and chronic granulomatous disease: Patients with X-linked chronic granulomatous disease (CGD), who carry inactivating mutations of NADPH oxidase (NOX2), exhibit a specific pathway of NET formation, which is independent of NADPH oxidase (11) (Figure 3).